Skip to main content

Table 2 Comparison of the clinical outcomes in the matched cohort

From: Cost-effectiveness of polymyxin B hemoperfusion for septic shock: an observational study using a Japanese nationwide administrative database

 

PMX (n = 965)

Control (n = 2895)

P value

28-day mortality, n (%)

162 (16.8)

692 (23.9)

 < 0.0001

Hospital mortality, n (%)

235 (24.4)

987 (34.1)

 < 0.0001

Length of hospital stay, days, median (IQR)

32 (18–51)

25 (15–45)

 < 0.0001

Ventilator free days, days, median (IQR)

19 (0–24)

15 (0–23)

 < 0.0001

Vasopressor free days, days, median (IQR)

25 (20–26)

24 (0–26)

 < 0.0001

CRRT free days (day), days, median (IQR)

23 (13–25)

20 (0–24)

 < 0.0001

  1. IQR Interquartile range, CRRT Continuous renal replacement therapy